CCP
BIO icon

Corient Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Corient Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-421
Closed -$237K – 693
2022
Q1 		$237K Buy
+421
New +$254K 0.02% 626
2021
Q3 		– Sell
-320
Closed -$206K – 701
2021
Q2 		$206K Buy
+320
New +$195K 0.02% 615

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Corient Capital Partners's BIO Position: Q2 2022 in Review

Corient Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 421 shares — an estimated $237K sold.

Corient Capital Partners first reported a position in BIO in Q2 2021 and held it in 2 quarters. The position peaked at $237K in Q1 2022. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

  • Corient Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
  • Corient Capital Partners sold 421 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $237K.
  • Corient Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 2 quarters.
  • Corient Capital Partners's Bio-Rad Laboratories Class A position peaked at $237K in Q1 2022.
  • 500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.